C120P: Tezepelumab Biosimilar, Human TSLP Monoclonal Antibody

Catalog No.: C120P | **Product Name:** Tezepelumab Biosimilar, Human TSLP Monoclonal Antibody

The research grade Tezepelumab biosimilar protein is for research use only (RUO). Recombinant human IgG2 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

PRODUCT SPECIFICATIONS

Catalog No.	C120P
Product Name	Tezepelumab Biosimilar, Human TSLP Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	thymic stromal lymphopoietin; TSLP
Summary	Recombinant Humanized IgG2 lambda Monoclonal Antibody.
Isotype	Human IgG2 lambda.
Source/Host	The anti-human TSLP monoclonal antibody tezepelumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade tezepelumab biosimilar specifically binds to the TSLP protein.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by tezepelumab.
Form Of Antibody	0.2 μM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Tezepelumab Biosimilar, Human TSLP Monoclonal Antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Tezepelumab biosimilar protein is for research use only (RUO). Recombinant human IgG2 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

REFERENCES & BACKGROUND

What is tezepelumab biosimilar research grade? Tezepelumab (trade name Tezspire) is a human monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), an epithelial-cell-derived cytokine that occupies an upstream position in the asthma inflammatory cascade. By binding to TSLP, tezepelumab prevents its interaction with the heterodimeric TSLP receptor, thereby inhibiting downstream signaling pathways involving multiple cell types and cytokines implicated in asthma pathophysiology. Tezepelumab is indicated for the add-on maintenance treatment of severe asthma in adult and pediatric patients aged 12 years and older. Tezepelumab biosimilar uses the same protein sequences as the therapeutic antibody tezepelumab.